Stephane Bancel, Chief Executive Officer at Moderna, Inc. (MRNA), sold 159,500 shares at $132.97 ($20.6M) on 2023-05-10, disclosed to the SEC on 2023-05-12.
Scheduled sale ($20.6M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $131.08 | 16,954 | $2.2M | 10.8% |
| 2 | $131.08 | 16,954 | $2.2M | 10.8% |
| 3 | $131.89 | 21,247 | $2.8M | 13.6% |
| 4 | $131.89 | 21,247 | $2.8M | 13.6% |
| 5 | $132.97 | 1,499 | $199K | 1.0% |
| 6 | $132.97 | 1,499 |
| $199K |
| 1.0% |
| 7 | $133.71 | 300 | $40K | 0.2% |
| 8 | $127.17 | 35,330 | $4.5M | 21.8% |
| 9 | $127.17 | 35,330 | $4.5M | 21.8% |
| 10 | $127.92 | 4,470 | $572K | 2.8% |
| 11 | $127.92 | 4,470 | $572K | 2.8% |
| 12 | $128.84 | 200 | $26K | 0.1% |
| Total | $129.42 avg | 159,500 | $20.6M | 100% |
| Filing → |
| MRNA | SELL | 2024-02-16 | $4.7M | — | Filing → |
| MRNA | SELL | 2023-06-30 | $6.6M | — | Filing → |
| MRNA | SELL | 2023-06-23 | $19.3M | — | Filing → |